Back to News
Market Impact: 0.35
BlossomHill Q2 Loss Widens; BH-30643 Advances, Balance Sheet Strengthens
Source: Nasdaq
Healthcare & BiotechIPOs & SPACsCompany FundamentalsCorporate Guidance & Outlook
BlossomHill Therapeutics reported Q2 2026 results highlighting regulatory progress for BH-30643 and continued advancement of its oncology pipeline. The company also strengthened its balance sheet following a $168.3 million initial public offering, improving funding capacity for clinical and regulatory development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash